"TAVR has been associated with better valve hemodynamics and a lower risk of structural valve deterioration over time compared with SAVR," researchers wrote. "This benefit may be particularly relevant for diabetes patients who face higher risks of vascular complications."

Healthcare companies from all over the world are showing off their newest cardiovascular offerings at CES 2025 in Las Vegas.

The popular GLP-1 receptor agonist appears to help limit adverse events and new-onset diabetes in patients with a history of CABG. Researchers shared the full study in the Journal of the American College of Cardiology.

Experts say the DASH diet, designed to lower blood pressure and improve heart health, is fairly flexible and associated with several key benefits. 

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

The HEARTS Act is focused on improving cardiomyopathy education and awareness while getting more AEDs in schools. The ACC, AHA and other medical societies have supported the bipartisan bill, which now heads to the president's desk to be signed into law.

Insulet accused multiple parties, including a rival CEO, of working together to copy its insulin pump technology and bring a "clone product" to market.